• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: Generics increase to more than 75% of all 2013 prescriptions in England, Wales

Report: Generics increase to more than 75% of all 2013 prescriptions in England, Wales

July 28, 2014
CenterWatch Staff

Usage of generic medicines in England and Wales increased to more than three-quarters of all NHS prescriptions in 2013, according to the latest figures supplied by the Health and Social Care Information Center (HSCIC).

Based on these data, generic medicines now save the NHS nearly $20.9 billion annually, according to the British Generic Manufacturers Association (BGMA), which represents more than 90% of the U.K. supply market. This is up from a saving in 2012 of nearly $18.7 billion.

Warwick Smith, director general of the BGMA, said, "These NHS figures underline the importance of the generics industry in the U.K., which provides crucial financial savings for the NHS allowing investment into new medicines. As well as the savings, the uptake of generics also increases patient access to vital medicines.”

The increase in generic prescriptions in 2013 was driven in part by the ongoing impact of several large volume originator products losing patent protection, such as atorvastatin, which helps to reduce the likelihood of heart attacks and strokes.

Competition from generic manufacturers of the medicine—brand name Lipitor—delivered the greatest decrease in cost of any medicine over the last year, a $211 million decrease from $283 million in 2012 to $72 million in 2013.

It also saw the greatest increase in the number of items dispensed, from 12.8 million in 2012 to 18.3 million in 2013, an increase of 5.5 million items. Generic competition allowed more than 40% of additional patients to receive this medicine, while reducing the cost to the NHS by almost 70%.

Smith said, "While focusing on the savings, it also is important to recognize that this allows the NHS to make further investment into the next generation of medicines and encourages greater innovation and research."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing